Catalyst Wire Dossier Catalyst Wire Dossier

Pelacarsen

pelacarsen · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

9 regulatory and trial events tracked for Pelacarsen, covering 2024-10-09 to 2026-07-17. Get the full timeline:

Most recent: Clinical Trial Results: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany [Phase 3]

See pricing